Patients with alopecia areata who did not respond to initial treatment with a JAKi or who did not maintain response may ...
Maria Hordinsky, MD, discusses the promise of Janus kinase (JAK) inhibitors in treating alopecia areata in the long term.
Delgocitinib vs PUVA shows comparable efficacy in chronic hand eczema with QoL benefits. Find out more about this real-world study.
JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster ...
Please provide your email address to receive an email when new articles are posted on . Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MIAMI BEACH, Fla. — Janus kinase inhibitors are an ...
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results